Johnson & Johnson (JNJ) Change in Acquisitions & Divestments (2009 - 2026)
Johnson & Johnson (JNJ) posted Change in Acquisitions & Divestments of $159.0 million for Q2 2026, down 23.92% sequentially from $209.0 million in Q1 2026, and down 78.37% YoY from $735.0 million in Q2 2025.
Johnson & Johnson (JNJ) Change in Acquisitions & Divestments (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Change in Acquisitions & Divestments for 18 years, with the latest figure at $159.0 million in Q2 2026.
- Quarterly Change in Acquisitions & Divestments fell 78.37% year-over-year to $159.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.1 billion (down 37.04% YoY) and the FY2025 annual result came in at $1.7 billion, down 32.53% from the prior year.
- Change in Acquisitions & Divestments retreated to $159.0 million in Q2 2026 per JNJ's latest filing, from $209.0 million in the prior quarter.
- Over five years, Change in Acquisitions & Divestments peaked at $24.8 billion in Q1 2023 and troughed at $159.0 million in Q2 2026.
- A 5-year average of $3.4 billion and a median of $731.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
- The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments increased 23.21% in 2023, then tumbled 91.95% in 2024.
- Over 5 years, Change in Acquisitions & Divestments stood at $6.3 billion in 2022, then sank by 42.84% to $3.6 billion in 2023, then sank by 91.95% to $290.0 million in 2024, then fell by 24.48% to $219.0 million in 2025, then fell by 27.4% to $159.0 million in 2026.
- According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $159.0 million, $209.0 million, and $219.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 159.00 Mn |
| Jun 28, 2026 | 159.00 Mn |
| Mar 29, 2026 | 209.00 Mn |
| Mar 29, 2026 | 209.00 Mn |
| Dec 28, 2025 | 219.00 Mn |
| Dec 28, 2025 | 219.00 Mn |
| Sep 28, 2025 | 489.00 Mn |
| Sep 28, 2025 | 489.00 Mn |
| Jun 29, 2025 | 735.00 Mn |
| Jun 29, 2025 | 735.00 Mn |
| Mar 30, 2025 | 218.00 Mn |
| Mar 30, 2025 | 218.00 Mn |
| Dec 29, 2024 | 290.00 Mn |
| Dec 29, 2024 | 290.00 Mn |
| Sep 29, 2024 | 466.00 Mn |
| Sep 29, 2024 | 466.00 Mn |
| Jun 30, 2024 | 727.00 Mn |
| Jun 30, 2024 | 727.00 Mn |
| Mar 31, 2024 | 979.00 Mn |
| Mar 31, 2024 | 979.00 Mn |